Texas Medicaid Designates Pegfilgrastim-cbqv on the Preferred Drug List

March 15, 2021

For 2021, Texas Medicaid has designated pegfilgrastim-cbqv (Udenyca^®, Coherus Biosciences) the preferred pegfilgrastim on the Preferred Drug List (PDL). Udenyca^® coverage details are available here.

Please contact marketaccess@coherus.com for additional information.

Posted 3/15/2021

Upcoming Events

ACCC Oncology Reimbursement Meeting | Reno

In Person November 4, 2026 at 8:00 AM PST255 North Virginia Street, Reno, NV, USAWhitney Peak Hotel Reno, Tapestry Collection by Hilton,

ACCC Oncology Reimbursement Meeting | Providence

In Person November 10, 2026 at 8:00 AM EST5 Avenue of the Arts, Providence, RI, USARenaissance Providence Downtown Hotel,

Trending Now on
ACCCBuzz Blog

Clear Pathways to Care: APPs and AHPs Expanding Access at the Wilmot Cancer Institute’s Breast Care Program

By championing and encouraging advanced practice providers and allied health professionals to work at the top of their licenses, Wilmot Cancer Institute offers comprehensive care close to home through its breast care program that vastly improves the patient experience.

#ACCCNOC: Care Between Visits, Removing Financial Barriers, and Policy Initiatives

On the final day of the 43rd National Oncology Conference, a series of interactive panel discussions explored innovative strategies for remote patient monitoring across the globe, improving quality and safety amidst complex treatments, financial challenges in precision medicine and clinical trials, and more.

#ACCCNOC: Igniting Innovation, Operationalizing CAR T and Bispecifics, and Whole-Person Support

Day two of the 43rd National Oncology Conference featured lively panel discussions on operationalizing CAR T-cell therapy and bispecific antibodies, building sustainable supportive care services, expanding access amid rising patient volumes, as well as presentations from the six 2026 ACCC Innovator Award Winners.

#ACCCNOC: The Psychosocial Oncology Professionals Symposium, the ACCC Presidential Address, and the 2026 ACCC Innovators

Day one of ACCC’s 43rd National Oncology Conference featured a national look at financial advocacy, the Psychosocial Oncology Professionals Symposium, announcement of the President’s Theme from 2026-2027 ACCC President Douglas Flora, MD, LSSBB, FACCC, and recognition of the 2026 ACCC Innovators.

View All ACCCBuzz Blogs

Recently Heard on
CANCER BUZZ Podcast

Live from NOC: Dr. Doug Flora's Presidential Address

Not a Revolution, an Evolution: AI and the Future of Cancer Care – [Video Podcast] Ep. 67

The Financial Reality of Bispecific Antibodies: What It Takes to Build and Sustain a Program - Podcast [Ep. 243]

Bringing CAR T-Cell Therapy to the Community Setting - Mini Podcast [Ep. 242]

View All Podcasts

Latest from Oncology Issues

View All Oncology Issues